Jerome Benedict Durso
CIK: 0001698665
Jerome Benedict Durso's purchase track record
How the stock did after each of Jerome Benedict Durso's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 4 since December 22, 2025
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-8.3%
3 months: -16.9%
Beat the S&P 500
0%
median -24.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2026 | ALT | $44K | pending | pending | — |
| 4/1/2026 | ALT | $47K | +1.0% | -8.3% | +16.4% |
| 3/6/2026 | ALT | $71K | -23.4% | -3.4% | +14.5% |
| 12/22/2025 | ALT | $52K | -16.9% | -29.2% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALT | ▲ Buy | Open Market | 15,000 | $44K | 8/13/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 15,000 | $47K | 4/1/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 20,000 | $71K | 3/6/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 12,500 | $52K | 12/22/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.